Engineering antigen-driven co-stimulation and T helper cell activity into TCR-T cells with CD8-41BB fusion receptors enhances anti-tumor activity

Ivy Dutta(Intellia Therapeutics (United States)), Aaron Prodeus(Intellia Therapeutics (United States)), Ian C. Miller(Intellia Therapeutics (United States)), Eliana Ruggiero(Vita-Salute San Raffaele University), Ishina Balwani(Intellia Therapeutics (United States)), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Birgit C. Schultes(Intellia Therapeutics (United States)), Yoko Kosaka(Oregon Health & Science University), Chiara Bonini(Vita-Salute San Raffaele University), Eleni Stampouloglou(Intellia Therapeutics (United States)), Jingyu Peng(Shanghai Clinical Research Center), Liz Cam(Intellia Therapeutics (United States)), Jesse L. Coy(Oregon Health & Science University), Jessica Mulkey(Oregon Health & Science University), J. Richard Bowen(Alfred I. duPont Hospital for Children), Lekshmi Maya(Intellia Therapeutics (United States)), Justin Oh(Intellia Therapeutics (United States)), James Peter(Intellia Therapeutics (United States)), Dai Liu(Intellia Therapeutics (United States)), Allie Luther(Intellia Therapeutics (United States)), Palak Sharma(Dr Panjabrao Deshmukh Krishi Vidyapeeth), Qingzhan Zhang(Intellia Therapeutics (United States)), Evan Lind(Oregon Health & Science University)
bioRxiv (Cold Spring Harbor Laboratory)
July 28, 2026
Cited by 0


Related Papers